Does Thalidomide Cause Second Generation Birth Defects?
- Professor Dick Smithells
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The proposed association between thalidomide and second generation birth defects is an improbable hypotheses which lacks, so far, any credible scientific foundation. However, the media have chosen to give it extensive coverage. So much so that even the hard-headed scientist may start wondering if there is anything in it. However, there is no reason to suppose that people with birth defects caused by exposure to thalidomide during embryonic life have any greater or lesser chance of producing children with birth defects. This appears to be the case in practice. The question could be reworded to, ‘Can thalidomide be responsible for identical, or similar, birth defects in 2 generations of the same family?’
For such a phenomenon to be possible, a mechanism must be proposed and there appear to be only 2 possible candidates. The first is that the defects in the parent, originating during embryonic life, have somehow been transmitted to the next generation. The second is that thalidomide is a mutagen as well as a teratogen.
The first mechanism can be excluded, since Lamarckism has long since been abandoned by scientists. The hypothesis that thalidomide is a mutagen and might be responsible for birth defects in the children of thalidomide-damaged people is without any scientific foundation. Birth defects appear to be no more common amongst the children of thalidomide-affected parents than in the general population. It is important that thalidomide-affected adults are firmly reassured on this point. Most of them have now completed their own families, but they may still worry about their grandchildren.
Therefore, unless and until further supportive evidence is reported by a separate and independent source, the answer to the question, ‘Can thalidomide cause second generation defects?’ is a very definite ‘No.’
- Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878–81 CrossRef
- McBride WG. Thalidomide may be a mutagen [letter]. BMJ 1994; 308: 1635–6 CrossRef
- Read AP. Thalidomide may be a mutagen [letter]. BMJ 1994; 308: 1636 CrossRef
- Smithells RW. Thalidomide may be a mutagen [letter]. BMJ 1994; 309: 477 CrossRef
- Tenconi R, Clementi M, Notari L, et al. Amniotic band sequence in child of thalidomide victim [letter]. BMJ 1994; 309: 1442 CrossRef
- Smithells RW, Newman CGH. Recognition of thalidomide defects. J Med Genet 1992; 29: 716–23 CrossRef
- Ashby J, Tinwell H. Is thalidomide teratogenic? Nature 1995; 375: 453 CrossRef
- Huang PHT, McBride WG. Thalidomide induced alteration in secondary structure of rat embryonic DNA in vivo. Teratog Carcinog Mutagen 1990; 10: 281–94 CrossRef
- Huang PHT, McBride WG. Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo. Teratog Carcinog Mutagen 1997; 17: 1–5 CrossRef
- Neubert D. Never-ending tales of the mode of the teratogenic action of thalidomide. Teratog Carcinog Mutagen 1997; 17: i–ii CrossRef
- Does Thalidomide Cause Second Generation Birth Defects?
Volume 19, Issue 5 , pp 339-341
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Paediatrics and Child Health, University of Leeds, Leeds, England